The Indian Pharmaceutical Market (IPM) clocked Rs 7161 crores in July 2014 and has grown at 7.2 per cent. In the corporate sector amongst the top 10, Sun Pharma grew by 14.2 per cent, Lupin by 13.2 per cent and Cipla by 9.5 per cent. Macleods grew at 27.9 per cent to become the tenth biggest corporate for the month of July 2014. With the portfolio of Elder, Torrent is now placed at sixteenth rank in IPM. 24 corporates have crossed the growth of IPM amongst the top 50. Akumentis has the highest growth of 49 per cent followed by Ajanta at 41.2 per cent and Apex at 40.9 per cent. 16 corporates showed double digit growths amongst the top 50.
Amongst the 11-20 ranked corporates, Macleods has the highest growth of 27.9 per cent followed by Ipca at 21.2 per cent and Aristo at 16.2 per cent. Amongst the 51-60 ranked corporates, Panacea grew at 36.9 per cent followed by Troikaa at 22.3 and Systopic 20.3 per cent. Amongst the 61-75 ranked corporates, Lincoln grew at 43.7 per cent followed by Corona at 36.3 per cent and Serdia at 19.6 per cent.
Indian companies have grown at 9.1 per cent versus 1.5 per cent for MNCs in July 2014. Amongst the top 50 in MNCs MSD and Janssen grew at 6.9 per cent and Ranbaxy at 5.7 per cent. Under the non-NLEM category, Indian companies de-grew at 11.1 per cent whereas MNCs de-grew at 2.5 per cent.
|
With Bonus Units at Full Value
|
(Val in Crs)
|
|||||||
|
Val in Crs
|
Rank
|
MAT July -14
|
Jul-14
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
78902
|
100.00
|
6.4
|
7161
|
100.00
|
7.2
|
||
| Abbott + Abbott HC + Novo |
1
|
1
|
4933
|
6.25
|
3.2
|
443
|
6.19
|
5.4
|
| Sun Pharma |
2
|
2
|
4269
|
5.41
|
15.7
|
387
|
5.41
|
14.4
|
| Cipla |
3
|
3
|
3867
|
4.90
|
5.9
|
344
|
4.81
|
9.5
|
| Zydus + Biochem |
4
|
4
|
3397
|
4.30
|
5.8
|
295
|
4.12
|
5.6
|
| Ranbaxy |
5
|
6
|
3055
|
3.87
|
1.8
|
266
|
3.72
|
5.7
|
| Mankind |
6
|
5
|
2790
|
3.54
|
4.9
|
272
|
3.80
|
9.1
|
| Glaxo |
7
|
9
|
2761
|
3.50
|
-16.4
|
244
|
3.40
|
-9.5
|
| Alkem + Cachet + Indchemie |
8
|
8
|
2698
|
3.42
|
7.2
|
248
|
3.46
|
1.0
|
| Lupin |
9
|
7
|
2649
|
3.36
|
12.3
|
249
|
3.47
|
13.2
|
| Pfizer + Wyeth |
10
|
11
|
2289
|
2.90
|
4.1
|
200
|
2.80
|
1.4
|
| Emcure + Zuventus |
11
|
12
|
2183
|
2.77
|
12.7
|
192
|
2.68
|
5.4
|
| Macleods |
12
|
10
|
2152
|
2.73
|
14.8
|
223
|
3.11
|
27.9
|
| Intas |
13
|
14
|
2043
|
2.59
|
14.4
|
185
|
2.59
|
12.9
|
| Sanofi India + Universal |
14
|
15
|
1956
|
2.48
|
-1.9
|
178
|
2.49
|
4.0
|
| Aristo |
15
|
13
|
1928
|
2.44
|
14.3
|
188
|
2.63
|
16.2
|
| Torrent |
16
|
16
|
1744
|
2.21
|
3.0
|
169
|
2.36
|
12.6
|
| Glenmark |
17
|
18
|
1702
|
2.16
|
15.8
|
150
|
2.10
|
9.6
|
| Dr. Reddys |
18
|
17
|
1679
|
2.13
|
7.2
|
154
|
2.15
|
11.9
|
| Micro + Bal |
19
|
19
|
1606
|
2.04
|
11.0
|
148
|
2.06
|
12.4
|
| Ipca |
20
|
20
|
1420
|
1.80
|
21.8
|
133
|
1.85
|
21.2
|
| USV |
21
|
21
|
1419
|
1.80
|
8.4
|
126
|
1.76
|
8.2
|
| Wockhardt |
22
|
22
|
1237
|
1.57
|
5.6
|
103
|
1.43
|
7.9
|
| Novartis |
23
|
23
|
1129
|
1.43
|
-2.5
|
99
|
1.38
|
-2.5
|
| Alembic |
24
|
24
|
1066
|
1.35
|
9.1
|
92
|
1.29
|
4.7
|
| FDC |
25
|
25
|
820
|
1.04
|
2.5
|
74
|
1.04
|
0.5
|
| Unichem |
26
|
26
|
798
|
1.01
|
8.3
|
72
|
1.00
|
13.1
|
| MSD + Fulford + Organon |
27
|
27
|
784
|
0.99
|
11.4
|
67
|
0.93
|
6.9
|
| Cadila |
28
|
28
|
679
|
0.86
|
16.6
|
59
|
0.83
|
3.9
|
| Indoco Remedies |
29
|
30
|
600
|
0.76
|
6.5
|
54
|
0.75
|
3.3
|
| Franco |
30
|
29
|
579
|
0.73
|
11.2
|
55
|
0.76
|
6.9
|
| Eris |
31
|
31
|
575
|
0.73
|
21.0
|
52
|
0.73
|
8.1
|
| Himalaya |
32
|
32
|
481
|
0.61
|
5.6
|
44
|
0.62
|
8.1
|
The DPCO 2013 containing molecules market was at –0.7 per cent whereas the non-DPCO market grew by 8.9 per cent resulting in an overall growth of 7.2 per cent for July 2014. NLEM category showed positive unit growth at 3.2 per cent. The DPCO 2013 portfolio for Pfizer degrew at 16.7 per cent, GSK de-grew at 7.9 per cent and Ranbaxy grew by 18.2 per cent.
From therapy perspective, 12 therapies have outgrown the IPM growth and eight therapies have double digit growths. The respiratory market de-grew at -1.4 per cent, gastrointestinal market grew at 7.6 per cent whereas the anti-infectives de-grew at 1.1 per cent. The anti-diabetic market grows at 28.3 per cent and cardiac at 10.6 per cent in chronic business. Derma market grew by 12.6 per cent and urology market at 24 per cent.
From the regional perspective, 14 regions have outgrown the IPM growth. The Odisha market grew the highest at 18.6 per cent followed by Mumbai market at 14.2 per cent, Telangana and Kolkata at 13.7 per cent. Three regions had negative growths in July 2014.
|
Val in Crs
|
MAT July 14
|
Month July 14
|
||
|
Super Group
|
Val in Crs
|
GR%
|
Val in Crs
|
GR%
|
| IPM |
78902
|
6.4
|
7161
|
7.2
|
| ANTI-INFECTIVES |
12739
|
-1.2
|
1160
|
-1.1
|
| CARDIAC |
9727
|
8.6
|
870
|
10.6
|
| GASTRO INTESTINAL |
8999
|
6.5
|
869
|
7.6
|
| VITAMINS / MINERALS / NUTRIENTS |
7093
|
6.8
|
661
|
7.5
|
| RESPIRATORY |
6119
|
8.0
|
473
|
-1.4
|
| ANTI DIABETIC |
5718
|
18.0
|
541
|
28.3
|
| PAIN / ANALGESICS |
5653
|
4.8
|
533
|
8.5
|
| NEURO / CNS |
4856
|
6.8
|
436
|
8.5
|
| DERMA |
4571
|
14.4
|
419
|
12.6
|
| GYNAECOLOGICAL |
4087
|
1.7
|
377
|
6.4
|
| OPHTHAL / OTOLOGICALS |
1420
|
9.9
|
132
|
10.3
|
| HORMONES |
1324
|
3.6
|
114
|
4.9
|
| ANTI-NEOPLASTICS |
1295
|
26.9
|
111
|
29.0
|
| VACCINES |
1161
|
-7.8
|
85
|
-19.1
|
| BLOOD RELATED |
1019
|
4.9
|
91
|
-1.1
|
| OTHERS |
936
|
5.4
|
86
|
12.1
|
| UROLOGY |
779
|
14.1
|
78
|
24.0
|
| ANTI MALARIALS |
619
|
0.2
|
55
|
-9.2
|
| SEX STIMULANTS / REJUVENATORS |
434
|
2.7
|
36
|
3.4
|
| STOMATOLOGICALS |
354
|
10.1
|
33
|
10.7
|
Amoxycillin + Clavulanic acid market grows at 9.30 per cent whereas Glimepiride + Metformin grows at 24.20 per cent at number two. The markets of Montelukast + Levocetirizine grew at 20.9 per cent, Atorvastatin grew by 12.7 per cent, Paracetamol at 10.8 per cent, Probiotic Microbes at 14.2 per cent, Vitamin D at 34.6 per cent, Voglibose + Metformin + Glimepiride market at 61 per cent, Paracetamol + Tramadol at 29.7 per cent, Rosuvastatin 25.7 per cent.
Glycomet-GP grows at 17.7 per cent, Mixtard at 14.9 per cent and Dexorange at 13 per cent amongst the top 10 brands. Amongst the brands who have gained ranks include Thyronorm (+39), Dolo (+36), Skinlite, Losar – H & Lantus (+11), Shelcal (+10), Dexorange (+9), Liv -52 (+8), Glycomet-GP (+6), Clavam (+4), amongst Top 100 brands over July 13.
Amongst the top brands in the IPM, Galvus Met (47.6 per cent), Duphaston (29.2 per cent), Lantus (19.7 per cent), Pan (18.2 per cent), Glycomet GP (17.7 per cent), Skinlite (17 per cent) grew fastest amongst top 30 brands over July 2013.
A total of 232 brands were launched in July 2014. LNBeta, Graviderm and Zerodol PG were the top NIs for the month of July 2014. There is a new category launched in the market – Aceclofenac + Pregabalin .
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net